Global market- Hemophilia A and B 2017 key players, share, trend, segmentation and forecast to 2026

Hemophilia A and B Market 

ReportsMonitor has added a report on Hemophilia A and B Market.

Hemophilia A and B are rare recessionary X-linked genetic need in the blood clotting factors VIII and IX, respectively, and are defined by the failure of blood to form normal clots after harm to veins and tissue. In the 7MM, patients with severe forms of the disease are increasingly treated on a prophylactic basis rather than on demand after bleeds. The frequent prophylactic infusions of rFVIII or rFIX begin from the first one or two years of life, often continuing through adulthood.

If you want sample of this Report -

https://www.reportsmonitor.com/request-sample/?post=362205

Summary

The hemophilia market has been dominated by short-acting rFVIII or FIX concentrates. However, in recent years the hemophilia market has become increasingly competitive due to the approval of extended half-life products that can reduce the burden associated with prophylaxis. These improvements have mainly benefited hemophilia B patients, while a substantial unmet need remains for hemophilia A patients and patients with inhibitors who do not respond to standard treatments.

Key Questions Answered

- What are the key drivers behind the increasing uptake and market penetration of the long-acting factor concentrates in hemophilia A and B, since their approval in 2014, and what is the trend in the use of long-acting factors in the forecast period?

- The hemophilia market is characterized by a number of unmet needs. What are the main unmet needs in this market? Will the pipeline drugs under development fulfil these unmet needs?

Scope

- Overview of hemophilia, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.

- Annualized hemophilia therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in nine patient segments and two treatment strategies (episodic and prophylactic treatment), forecast from 2016 to 2026.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications for the hemophilia therapeutics market.

If you want to check Discount on this Report -

https://www.reportsmonitor.com/check-discount/?post=362205

Table Of Contents

1 Table of Contents1 Table of Contents 2

1.1 List of Tables 7

1.2 List of Figures 11

2 Executive Summary 12

2.1 Sales for Hemophilia A and B Recombinant Therapies by Region, 2016-2026 13

2.2 Long-Acting rFVIIIs Have Not Lived Up to Expectations 14

2.3 Inhibitor Segment to Devalue Post-Alternative Coagulation Promoter Launch 16

2.4 Roche’s Emicizumab to Radically Impact Hemophilia A and Inhibitor Segments 16

2.5 Treatment Cost to Remain a Major Unmet Need 16

2.6 New Comers to Take Over Market Space From Established Companies 17

2.7 What Do Physicians Think? 18

3 Introduction 19

3.1 Catalyst 19

3.2 Related Reports 20

3.3 Upcoming Related Reports 21

Continue.......

Full Report Access -

https://www.reportsmonitor.com/pharmapoint-hemophilia-a-and-b-global-drug-forecast-and-market-analysis-to-2026/

Reports Monitor is a platform to meet the market research and business intelligence requirements. Our aim is to change the dynamics of the Market Research industry by providing quality intelligence backed by data. Your requirement for market forecasting is fulfilled by our exclusive quantitative and analytics driven intelligence. Decision makers can now rely on our distinct data gathering methods to get factual market forecasting and detailed analysis.

Address: Office C & D - 4th Floor, Siddhi Towers, Above Rupee Bank, Kondhwa Road, Pune 411048, Maharashtra, India

This release was published on openPR.